Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study.
Fiche publication
Date publication
juillet 2021
Journal
Targeted oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier
Tous les auteurs :
Callejo A, Faouzi S, Bouché O, Bertucci F, Chevalier T, Isambert N, Duffaud F, Collard O, Penel N, Terrier P, Mir O, Blay JY, Le Cesne A
Lien Pubmed
Résumé
Retrospective analyses suggest that patients with advanced KIT exon 9-mutated gastrointestinal stromal tumors (GISTs) receiving imatinib 800 mg (rather than 400 mg) daily have better outcomes. In the adjuvant setting, the question of the optimal dose of imatinib remains unsettled.
Mots clés
Adolescent, Adult, Aged, Aged, 80 and over, Exons, genetics, Female, Gastrointestinal Stromal Tumors, drug therapy, Humans, Imatinib Mesylate, pharmacology, Male, Middle Aged, Mutation, Protein Kinase Inhibitors, pharmacology, Retrospective Studies, Young Adult
Référence
Target Oncol. 2021 07;16(4):485-492